Biggest News Aggregation in the World
📰 Generic Name News

Page 2 - Generic Name News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Generic Name. Real-time updates on events, politics, business and more.

Eisai Launches In-house Developed Anti-insomnia Drug Dayvigo (Lemborexant) In Hong Kong

Eisai Launches In-house Developed Anti-insomnia Drug Dayvigo (Lemborexant) In Hong Kong First Launch For Dayvigo In Asia Outside Of Japan TOKYO, July 1, 2021 - (JCN Newswire) - Eisai Co., Ltd. announced today that its Hong Kong subsidiary Eisai (Hong Kong) Co., Ltd. has launched the in-house-discovered and developed orexin receptor antagonist DAYVIGO (generic name: lemborexant) for the treatment of adults with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance. Ei...
United States Hong Kong Asia Hong Kong Eisai Hong Kong Co Ltd Eisai Co Ltd Institute Of Medicine

Worldwide CNS Therapeutics Industry to 2025 - Awareness Campaigns Launched by Pharma Companies to Benefit the Market

Share this article Share this article ResearchAndMarkets.coms offering. The global market for CNS Therapeutics is projected to reach US$137.7 billion by 2025, driven by the urgent need to address the unmet medical needs of neurological disorders. Diseases of the brain and mind range from epilepsy, stroke, migraine, Alzheimer`s, Parkinson`s, dementia, multiple sclerosis, brain injuries, neuroinfections, schizophrenia, psychosis and other mental disorders. With unmet needs continuing to persist,...
United States United Kingdom Effexor Venlafaxine Epidiolex Cannabidiol Purdue Pharma Eli Lilly Emgality

New Drug Approval for in-House Developed Anti-Insomnia Drug Dayvigo (Lemborexant) in Hong Kong

New Drug Approval for in-House Developed Anti-Insomnia Drug Dayvigo (Lemborexant) in Hong Kong First Drug Approval for Dayvigo in Asia Outside of Japan TOKYO, Mar 2, 2021 - (JCN Newswire) - Eisai Co., Ltd. announced that its Hong Kong subsidiary Eisai (Hong Kong) Co., Ltd. has obtained approval for the in-house-discovered and developed orexin receptor antagonist DAYVIGO (generic name: lemborexant) for the treatment of adults with insomnia, characterized by difficulties with sleep onset and/or s...
United States Hong Kong Kostenloser Wertpapierhandel Asia Hong Kong Eisai Hong Kong Co Ltd Eisai Co Ltd

Vaccination in pregnancy (VIP)

Inadvertent vaccination in pregnancy (VIP) Advice for health professionals on pregnant women who are inadvertently vaccinated against coronavirus (COVID-19), chicken pox (varicella), shingles or measles, mumps, rubella. From: Contents PHE) follows up women who have inadvertently been given certain vaccines in pregnancy ( VIP) across the UK. These women would therefore not have been aware they were pregnant at the time of vaccination. Through GPs and surgeries to better inform: pregna...
United Kingdom Sanofi Pasteur Helen Campbell European Medicines Agency Electronic Compendium Public Health England Health Service Regulation
Source: gov.uk

Stay Updated with Latest News

Get breaking news updates delivered to your inbox

Browse All News →

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science